Two studies led by the Bellvitge Biomedical Research Institute (IDIBELL<\/a>), the Catalan Institute of Oncology (ICO<\/a>) and the Bellvitge Hospital show that non-invasive samples such as urine, cytology, or a vaginal self-sample<\/strong>, through small tampon-like devices, would be applicable for endometrial cancer detection. This would be a reliable and easy-to-use tool that would predict the prognosis of each woman and adjust the treatment to her needs<\/strong>.<\/p>\n
The two studies published in the scientific journals Clinical Cancer Research<\/a> and eBioMedicine<\/a> have had the participation of epidemiologists, gynecologists, pathologists, geneticists, and bioinformaticians from IDIBELL, the Catalan Institute of Oncology, and the Bellvitge University Hospital.<\/p>\n